IMproved PREdiction of Severe Sepsis in the Emergency Department
NCT ID: NCT01392508
Last Updated: 2017-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
759 participants
OBSERVATIONAL
2011-03-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
NCT03113721
Heparin Binding Protein in Early Sepsis Diagnosis
NCT03295825
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
NCT03682003
Evaluation of the Heparin Binding Protein Levels in Sepsis
NCT02533011
Sepsis Assessment in Belgian Emergency Rooms
NCT02424721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected Infection
* one or more SIRS criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axis Shield Diagnostics Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Linder
Role: PRINCIPAL_INVESTIGATOR
Skanes Universitetssjukhus I Lund, Sweden
Magnus Paulsson
Role: PRINCIPAL_INVESTIGATOR
Skanes universitetssjukhuset i Malmo
Patrik Nyberg
Role: PRINCIPAL_INVESTIGATOR
Universitetssjukhuset i Linkoping
Anna Lange-Jendeberg
Role: PRINCIPAL_INVESTIGATOR
Universitetssjukhuset i Orebro
Ryan Arnold
Role: PRINCIPAL_INVESTIGATOR
The Cooper Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cooper University Hospital
Camden, New Jersey, United States
Universitetssjukhuset i Linkoping
Linköping, , Sweden
Skanes Universitetssjukhus i Lund
Lund, , Sweden
Skanes Universitetssjukhuset i Malmo
Malmo, , Sweden
Universitetssjukhuset i Orebro
Örebro, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange A, Paulsson M, Nyberg P, Russell JA, Pritchard D, Christensson B, Akesson P. Heparin-Binding Protein Measurement Improves the Prediction of Severe Infection With Organ Dysfunction in the Emergency Department. Crit Care Med. 2015 Nov;43(11):2378-86. doi: 10.1097/CCM.0000000000001265.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-FMHBP-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.